Repercussion of mitochondria deformity induced by anti-Hsp90 drug 17AAG in human tumor cells

Drug Target Insights

Volumn 2011, Issue 5, 2011, Pages 11-32

  Vishal, Chaturvedi ^a   Kumar, Jonnala Ujwal ^a   Swamy, Cherukuvada Veera Brahmendra ^a   Nandini, Rangaraj ^a   Srinivas, Gunda ^a   Kumaresan, Rathinam ^a,b   Shashi, Singh ^a   Sreedhar, Amere Subbarao ^a  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^b KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

Author keywords

17AAG; Hsp90; Mitochondria; Tumor cells; m

Indexed keywords

CISPLATIN; CURCUMIN; CYTOCHALASIN D; CYTOCHROME C; DIGITONIN; HEAT SHOCK PROTEIN 90; HYDROGEN PEROXIDE; NOVOBIOCIN; PACLITAXEL; RADICICOL; REACTIVE OXYGEN METABOLITE; TANESPIMYCIN; VINCRISTINE;

ARTICLE; CELL VACUOLE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER MITOCHONDRION; MALE; MASS SPECTROMETRY; MITOCHONDRIAL DEFORMITY; MITOCHONDRIAL ELONGATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MITOCHONDRION SWELLING; NEUROBLASTOMA CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEOMICS; TUMOR CELL; UTERINE CERVIX CANCER;

EID: 80053907818     PISSN: None     EISSN: 11773928     Source Type: Journal    
DOI: 10.4137/DTI.S6582     Document Type: Article

References (57)

1. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. The 90-kDa molec ular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther. 1998;79:129-68.
2. Wandinger SK, Richter K, Buchner J. The Hsp90 chaperone machinery. JBiol Chem. 2008;283:18473-7.
3. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003;228:111-33.
4. Powers MV, Workman P. Targeting of multiple signaling by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer. 2006;13: S125-135.
5. Vanden Berghe T, Kalai M, van Loo G, Declercq W, Vandenabeele P. Disruption of HSP90 function reverts tumor necrosis factor-induced necrosis to apoptosis. J Biol Chem. 2003;278:5622-9.
6. Debatin K, Poncet D, Kroemer G. Chemotherapy: targeting the mitochon drial death pathway. Oncogene. 2002;21:8786-803.
7. Tzagoloff A. Mitochondria, Plenum Press, New York, NY, USA; 1982.
8. Hileman EO, Achanta G, Huang P. Superoxide dismutase: an emerging target for cancer therapeutics. Expert Opin Ther Targets. 2001;5:697-710.
9. Van Waveren C, Sun Y, Cheung HS, Moraes CT. Oxidative phosphorylation dysfunction modulates expression of extracellular matrix-remodeling genes and invasion. Carcinogenesis. 2006;27:409-18.
10. Warburg O. Metabolism of Tumors, Arnold Constable, London, UK; 1930.
11. Garcea R, Canuto RA, Guatero B, Biocca M, Feo F. Phospholipid composition of inner and outer mitochondrial membranes isolated from Yoshida hepatoma AH-130. (1980) Cancer Lett. 1980;11:133-9.
12. Kluza J, Gallego MA, Loyens A, etal. Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. Cancer Res. 2006;66:3177-87.
13. Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer. 2002;9:1-9.
14. Vo TD, Palsson BO. Building the power house: recent advances in mito- chondrial studies through proteomics and systems biology. Am J Physiol Cell Physiol. 2007;292:C164-77.
15. Kroemer G. Mitochondrial control of apoptosis: an introduction. Biochem Biophys Res Commun. 2003;304:433-5.
16. Rube DA, van der Bliek AM. Mitochondrial morphology is dynamic and varied. Mol Cell Biochem. 2003;256-7:331-9.
17. Skulachev VP. Mitochondrial filaments and clusters as intracellular power- transmitting cables. Trends Biochem Sci. 2001;26:23-9.
18. Kroemer G. Cancer: defeating the immortal. Cancer Biol Ther. 2007;6: 1324-8.
19. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
20. Sreedhar AS, Soti C, Csermely P. Hsp90 inhibition: a new strategy to inhibit protein kinases. Biochim Biophys Acta. 2004;1697:233-42.
21. Neckers L, Kern A, Tsutsumi S. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Chem Biol. 2007;14:1204-6.
22. Bereiter-Hahn J. Behavior of mitochondria in the living cell. Inst Rev Cytol. 1990;122:1-63.
23. Margineantu DH, Emerson CB, Diaz D, Hockenbery DM. Hsp90 inhibition decreases mitochondrial protein turnover. PLoS ONE. 2007;2:e1066.
24. Diaz G, Setzu MD, Zucca A, Isola R, et al. Subcellular heterogeneity of mitochondrial membrane potential: relationship with organelle distribution and intercellular contacts in normal, hypoxic and apoptotic cells. J Cell Sci. 1999;112:1077-84.
25. Kamal A, Thao L, Sensintaffar J, etal. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90inhibitors. Nature. 2003;425:407-10.
26. Gerencser AA, Doczi J, Torocsik B, Bossy-Wetzel E, Adam-Vizi V. Mitochondrial swelling measurement in situ by optimized spatial filtering: astrocyte-neuron differences. Biophys J. 2008;95:2583-98.
27. Lehninger AL. Water uptake and extrusion by mitochondria in relation to oxidative phosphorylation. Physiol Rev. 1962;42:467-517.
28. He L, Lemasters JJ. Regulated and unregulated mitochondrial permeability transition pores: a new paradigm of pore structure and function. FEBS Lett. 2002;512:1-7.
29. Skulachev VP. Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett. 1998;423:275-80.
30. Vayssier-Taussat M, Kreps SE, Adrie C, Dall'Ava J, Christiani D, Polla BS. Mitochondrial membrane potential: a novel biomarker of oxidative environmental stress. Environ Health Perspect. 2002;110:301-5.
31. Mitchell P. Keilin's respiratory chain concept and its chemiosmotic consequences. Science. 1979;206:1148-59.
32. Jensen RE. Control of mitochondrial shape. Curr Opin Cell Biol. 2005;17: 384-8.
33. Schulte TW, Akinaga S, Soga S, et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones. 1998;3:100-8.
34. Ishida R, Takaoka Y, Yamamoto S, et al. Cisplatin differently affects amino terminal and carboxyl terminal domains of HSP90. FEBS Letts. 2008;582:3879-83.
35. Donnelly A, Blahh BSJ. Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide-binding Pocket. Curr Med Chem. 2008;15: 2702-17.
36. Tinari A, Garofalo T, Sorice M, Esposti MD, Malorni W. Mitoptosis: different pathways for mitochondrial execution. Autophagy. 2007;3: 282-4.
37. Safiulina D, Veksler V, Zharkovsky A, Kaasik A. Loss of mitochondrial membrane potential is associated with increase in mitochondrial volume: physiological role in neurones. Cell Physiol. 2006;206:347-53.
38. Dlaskova A, Hlavata L, Jezek P. Oxidative stress caused by blocking of mitochondrial complex I H(+) pumping as a link in aging/disease vicious cycle. Int J Biochem Cell Biol. 2008;40:792-1805.
39. Wang X, Zuo X, Kucejova B, Chen XJ. Reduced cytosolic protein synthesis suppresses mitochondrial degeneration. Nat Cell Biol. 2008;10: 1090-7.
40. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:63-398.
41. Sreedhar AS, Mihaly K, Pato B, et al. Hsp90 inhibition accelerates cell lysis. Anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibi- tors involving both superoxide- and Hsp90-dependent events. J Biol Chem. 2003;278:35231-40.
42. Tanaka T, Kaneda Y, Li TS, Matsuoka T, Zempo N, Esato K. Digitonin enhances the antitumor effect of cisplatin during isolated lung perfusion. Ann Thorac Surg. 2001;72:1173-8.
43. Brustovetsky N, Brustovetsky T, Jemmerson R, Dubinsky JM. Calcium- induced cytochrome c release from CNS mitochondria is associated with the permeability transition and rupture of the outer membrane. J Neurochem. 2002;80:207-18.
44. Vercesi AE, Bernardes CF, Hoffmann ME, Gadelha FR, Docampo R. Digitonin permeabilization does not affect mitochondrial function and allows the determination of the mitochondrial membrane potential of T{stroke}rypanosoma cruzi in situ. J Biol Chem. 1991;266:14431-4.
45. Gene Ontology Consortium. The gene ontology in 2010: extensions and refinements. Nucleic Acids Res. 2010;38:D331-5.
46. Sayers EW, Barrett T, Benson DA etal. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2009;37: D5-15.
47. Nardai G, Schnaider T, Soti C, et al. Characterization of the 90 kDa heat shock protein (Hsp90) -associated ATP/GTPase. J Biosci. 1996;21: 179-90.
48. Oslon M, Kronbluth S. Mitochondria in apoptosis and human disease. Curr Mol Med. 2001;1:91-122.
49. Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chap-erone network. Cell. 2007;131:257-70.
50. Kang BH, Siegelin MD, Plescia J, etal. Preclinical characterization of mito- chondria-targeted small molecule hsp90inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res. 2010;16:4779-88.
51. Kang BH, Plescia J, Song HY, et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. JClin Invest. 2009;119:454-64.
52. Nunnari J, Marshall WF, Straight A, Murray A, Sedat JW, Walter P. Mitochondrial transmission during mating in Saccharomyces cerevi- siae is determined by mitochondrial fusion and fission and the intramitochondrial segregation of mitochondrial DNA. Mol Biol Cell. 1997;8: 1233-42.
53. Suttitanamongkol S, Gear AR, Polanowska-Grabowska R. Geldanamycin disrupts platelet-membrane structure, leading to membrane permeabilization and inhibition of platelet aggregation. Biochem J. 2000;345 Pt 2: 307-14.
54. Mooth VK, Bunkenborg J, Olsen JV, et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell. 2003;115:629-40.
55. Chen X, Li J, Hou J, Xie Z, Yang F. Mammalian mitochondrial proteomics: insights into mitochondrial functions and mitochondria-related diseases. Expert Rev Proteomics. 2010;7:333-45.
56. O'Farrell PH. High resolution two-dimensional electrophoresis of protein. JBiol Chem. 1975;250:4007-21.
57. Hinshaw JE. Dynamin and its role in membrane fission. Annu Rev Cell Dev Biol. 2000;16:483-519